Due to growth in its pharmaceutical and contrast manufacturing business, contrast agent developer E-Z-EM plans to expand the facilities of its Canadian subsidiary, E-Z-EM Canada. The Westbury, NY, company will rent an additional 46,000 square feet
Due to growth in its pharmaceutical and contrast manufacturing business, contrast agent developer E-Z-EM plans to expand the facilities of its Canadian subsidiary, E-Z-EM Canada. The Westbury, NY, company will rent an additional 46,000 square feet adjacent to E-Z-EM Canadas existing 70,000-square-foot facility in Montreal. E-Z-EM Canada will occupy the new site in March, and has the option to lease additional space or buy the facility in the future. E-Z-EM Canada attributed its need for a larger site to increased sales of its major product lines in the past two years, according to Pierre-Andre Ouimet, president.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.